Liquidia Corporation (LQDA)


Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Liquidia Corporation ("Liquidia" or "the Company") (NASDAQ: LQDA). The investigation concerns whether Liquidia and certain of its officers and/or directors have violated federal securities laws.


On November 25, 2020, Liquidia revealed that the U.S. Food and Drug Administration (“FDA”) had issued a complete response letter (“CRL”) for its New Drug Application (“NDA”) for LIQ861 (treprostinil), inhalation powder for the treatment of pulmonary arterial hypertension (“PAH”). Liquidia said that “[i]n the CRL, the FDA stated that it is unable to approve the NDA at this time,” citing “the need for additional information and clarification on chemistry, manufacturing and controls (CMC) data pertaining to the drug product and device biocompatibility.” Following this news, Liquidia stock dropped over 5% to close at $2.94 per share on November 25, 2020.


If you are aware of any facts relating to this investigation, or purchased Liquidia shares, you can assist this investigation by visiting contacting the firm. You can also contact Peretz Bronstein or his Investor Relations Analyst, Yael Hurwitz of Bronstein, Gewirtz & Grossman, LLC: 212-697-6484. 

Bronstein, Gewirtz & Grossman, LLC is a corporate litigation boutique.  Our primary expertise is the aggressive pursuit of litigation claims on behalf of our clients.  In addition to representing institutions and other investor plaintiffs in class action security litigation, the firm’s expertise includes general corporate and commercial litigation, as well as securities arbitration. Attorney advertising. Prior results do not guarantee similar outcomes.

© 2020 Bronstein, Gewirtz & Grossman, LLC

  • Twitter Social Icon
  • LinkedIn

BG&G is not affiliated to any of these companies. All respective trademarks are owned by the respective companies.